AstraZeneca's IL-33-targeting antibody tozorakimab has made the grade in two phase 3 chronic obstructive pulmonary disease (COPD) trials, raising the prospects of a class that has recorded some ...

Abstract: Current Generative AI (GenAI)-based academic counseling systems suffer from some limitations including passive response modes, and the inability to promote systematic exploration of complex ...

Abstract: A concept map is a graphical tool used to organize and represent knowledge or information visually. It consists of a collection of concepts or ideas that are linked together by relationships ...

Hyundai used the Big Apple to make one of its biggest new product splashes in recent years. At the 2026 New York auto show, the Korean automaker, which is celebrating 40 years in America, took the ...

NCDOT opened a community engagement center for the project following community pushback, aiming to gather input as early designs continue to develop. Democrats float 25th Amendment commission for ...

Add Yahoo as a preferred source to see more of our stories on Google. The North Carolina Department of Transportation opened a new community engagement center Monday, aiming to rebuild trust and ...

There are over 16 million people in America diagnosed with COPD however millions more are living with COPD but do not know it, yet. There is no cure for COPD, which includes emphysema and chronic ...

AstraZeneca’s chronic obstructive pulmonary disease (COPD) candidate has hit the mark in a pair of phase 3 trials, delivering broad efficacy with a mechanism that yielded mixed data for Roche and ...

AstraZeneca’s IL-33 blocker, tozorakimab has significantly reduced the annualised rate of COPD exacerbations as an adjuvant to SoC inhaled therapy over placebo in two Phase III studies. Credit: ...

AstraZeneca didn’t release complete data from the trials, called Oberon and Titania, stating that they will be disclosed at an upcoming medical meeting. Those details will be closely watched.